Strategic Initiative

Slingshot members are tracking this corporate initiative:

Ocular Therapeutics (OCUL) and Regeneron (REGN) Agree to Develop a Sustained-Release Formulation of Aflibercept for Wet Age-Related Macular Degeneration (Wet AMD)

Source Link:: http://investors.ocutx.com/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2211430

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

REGN

100%

OCUL

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Oct 13, 2016

Projected Implementation:

Q4, 2016

Relevance Tracked Until:

Q4, 2017

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Strategic Initiative, Aflibercept, Wet Age-related Macular Degeneration, Wet Amd, Sustained-release Formulation, Product Development